Tags

Type your tag names separated by a space and hit enter

Gastric Neuroendocrine Tumors (Carcinoids).
Curr Gastroenterol Rep 2019; 21(4):13CG

Abstract

PURPOSE OF REVIEW

The diagnosis of gastric neuroendocrine tumors (NETs) is being made with increased frequency likely as a result of more upper endoscopies being done for unrelated reasons. It is therefore vital that gastroenterologists become familiar with the basic work-up and management of patients found to have these tumors. This review describes the classification, pathophysiology, clinical characteristics, and treatment options of the different gastric NETs.

RECENT FINDINGS

In addition to the three traditional subtypes of gastric NETs, additional cases associated with achlorhydria and appropriate hypergastrinemia may exist. The management of gastric NETs between 1 and 2 cm in size remains controversial and needs to be individualized. Gastric NETs are uncommon but are now diagnosed more frequently. This review highlights the role of hypergastrinemia in their development and the controversies around their management.

Authors+Show Affiliations

Division of Gastroenterology and Hepatology, Hospital of the University of Pennsylvania, Perelman School of Medicine, 3400 Civic Center Boulevard, Philadelphia, PA, 19104, USA.Division of Gastroenterology and Hepatology, Hospital of the University of Pennsylvania, Perelman School of Medicine, 3400 Civic Center Boulevard, Philadelphia, PA, 19104, USA. David.metz@uphs.upenn.edu.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

30868284

Citation

Gluckman, Craig R., and David C. Metz. "Gastric Neuroendocrine Tumors (Carcinoids)." Current Gastroenterology Reports, vol. 21, no. 4, 2019, p. 13.
Gluckman CR, Metz DC. Gastric Neuroendocrine Tumors (Carcinoids). Curr Gastroenterol Rep. 2019;21(4):13.
Gluckman, C. R., & Metz, D. C. (2019). Gastric Neuroendocrine Tumors (Carcinoids). Current Gastroenterology Reports, 21(4), p. 13. doi:10.1007/s11894-019-0684-7.
Gluckman CR, Metz DC. Gastric Neuroendocrine Tumors (Carcinoids). Curr Gastroenterol Rep. 2019 Mar 12;21(4):13. PubMed PMID: 30868284.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Gastric Neuroendocrine Tumors (Carcinoids). AU - Gluckman,Craig R, AU - Metz,David C, Y1 - 2019/03/12/ PY - 2019/3/15/entrez PY - 2019/3/15/pubmed PY - 2019/8/3/medline KW - Gastric carcinoid KW - Hypergastrinemia KW - Netazepide KW - Neuroendocrine tumor (NET) SP - 13 EP - 13 JF - Current gastroenterology reports JO - Curr Gastroenterol Rep VL - 21 IS - 4 N2 - PURPOSE OF REVIEW: The diagnosis of gastric neuroendocrine tumors (NETs) is being made with increased frequency likely as a result of more upper endoscopies being done for unrelated reasons. It is therefore vital that gastroenterologists become familiar with the basic work-up and management of patients found to have these tumors. This review describes the classification, pathophysiology, clinical characteristics, and treatment options of the different gastric NETs. RECENT FINDINGS: In addition to the three traditional subtypes of gastric NETs, additional cases associated with achlorhydria and appropriate hypergastrinemia may exist. The management of gastric NETs between 1 and 2 cm in size remains controversial and needs to be individualized. Gastric NETs are uncommon but are now diagnosed more frequently. This review highlights the role of hypergastrinemia in their development and the controversies around their management. SN - 1534-312X UR - https://www.unboundmedicine.com/medline/citation/30868284/Gastric_Neuroendocrine_Tumors_(Carcinoids) L2 - https://dx.doi.org/10.1007/s11894-019-0684-7 DB - PRIME DP - Unbound Medicine ER -